Drugs / DTaP5-IPV-Hib-HepB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00362427 | Aug 2006 → Feb 2009 | diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP₅-IPV-Hib-HepB | “Combination diphtheria-tetanus-5 component acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (DTaP5-IPV-Hib-HepB) administered...” PMID 24346596 ↗ Jan 20141“BACKGROUND: DTaP₅-IPV-Hib-HepB, an investigational hexavalent combination vaccine, was evaluated for safety and immunogenicity, when administered to infants with heptavalent...” PMID 23241989 ↗ Jan 2013 |
| Modality | Vaccine | “an investigational hexavalent combination vaccine” PMID 23241989 ↗ Jan 2013 |
| Route | Intramuscular | “0.5 mL, 4 doses, IM” NCT00362427 ↗ |